uniQure (NASDAQ:QURE) Raised to “Overweight” at Barclays

uniQure (NASDAQ:QURE) was upgraded by analysts at Barclays from an “equal weight” rating to an “overweight” rating in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage presently has a $65.00 price objective on the biotechnology company’s stock. Barclays‘s price objective would suggest a potential upside of 34.97% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $15.00 to $60.00 in a report on Monday, March 9th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research report on Wednesday. Leerink Partners reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research note on Monday, March 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.42.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $48.16 on Thursday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $3.04 billion, a PE ratio of -13.84 and a beta of 0.98. The firm’s 50 day moving average price is $23.55 and its 200-day moving average price is $21.90. uniQure has a twelve month low of $8.73 and a twelve month high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Equities research analysts expect that uniQure will post -3.64 EPS for the current year.

Insiders Place Their Bets

In related news, Director Robert Gut sold 7,552 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $26.05, for a total transaction of $196,729.60. Following the completion of the sale, the director owned 27,435 shares in the company, valued at approximately $714,681.75. This trade represents a 21.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 10,000 shares of uniQure stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.85, for a total value of $278,500.00. Following the sale, the director directly owned 43,254 shares in the company, valued at $1,204,623.90. This trade represents a 18.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 101,054 shares of company stock valued at $2,655,791. Insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc grew its holdings in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after buying an additional 738,897 shares in the last quarter. Quinn Opportunity Partners LLC bought a new stake in uniQure in the 3rd quarter worth approximately $6,281,000. Farallon Capital Management LLC raised its holdings in shares of uniQure by 3,935.7% during the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after acquiring an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new stake in shares of uniQure during the 3rd quarter worth approximately $8,599,000. Institutional investors own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now appears to support a near-term BLA submission for AMT-130, improving the odds of accelerated approval for Huntington’s disease. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight, citing the improved regulatory outlook and raising its price target to $61. Seeking Alpha
• Neutral Sentiment: The company disclosed insider sales by directors and executives, including recent transactions by Madhavan Balachandran and Jeannette Potts, which may draw attention but were executed under a pre-arranged trading plan in at least one case.
• Neutral Sentiment: Analyst opinions remain mixed overall, with recent price targets ranging widely, showing that expectations for the stock are still highly dependent on FDA and clinical execution.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.